OncLive TV

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

Shilpa Gupta, MD, shares updates from the frontlines and discusses how she is handling the COVID-19 pandemic.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the use of pathologic complete response (pCR) as a way to classify risk status in HER2-positive breast cancer.

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

David O’Malley, MD, discusses the current state of immunotherapy in ovarian cancer.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Gonzalo Sapisochin, MD, discusses the benefits of living donor liver transplantation in hepatocellular carcinoma.

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Andre Goy, MD, MS, discusses the paradigm shift in the treatment of patients with mantle cell lymphoma that has occurred over the past decade.

Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast cancer.

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.